Literature DB >> 16272395

Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin.

Jae-Chul Lee1, Kenji Yokota, Hideyuki Arimitsu, Hyun-Jung Hwang, Yoshihiko Sakaguchi, Jinhua Cui, Kouichi Takeshi, Toshihiro Watanabe, Tohru Ohyama, Keiji Oguma.   

Abstract

Clostridium botulinum type B strain produces two forms of progenitor toxin, 16S and 12S. The 12S toxin is formed by association of a neurotoxin (NTX) and a non-toxic non-haemagglutinin (NTNH), and the 16S toxin is formed by conjugation of the 12S toxin with a haemagglutinin (HA). HA consists of four subcomponents designated HA1, HA2, HA3a and HA3b. When mice were immunized with formalin-detoxified NTX, 12S or 16S, a significantly greater amount of anti-NTX antibody (Ab) was produced in the mice injected with 16S than in NTX- or 12S-injected mice. Immunization with NTX mixed with HA1 and/or HA3b also increased the anti-NTX Ab production, whereas NTX mixed with HA2 did not, indicating that HA1 and HA3b have adjuvant activity. This was further confirmed by immunizing mice with human albumin (Alb) alone or Alb mixed with either HA1 or HA3b. When mouse-spleen cells were stimulated with NTX, 16S or different HA subcomponents, 16S, HA1, HA3b and the mixture of HA1 and HA3 significantly increased interleukin 6 (IL6) production compared with NTX alone. Transcription of IL6 mRNA was low after stimulation with NTX alone, but increased to 16S-stimulation levels when NTX was mixed with HA1 or HA3b. In flow cytometry using labelled Abs against CD3 and CD19, the percentage of CD19 cells was higher following stimulation with 16S or NTX mixed with HA1 or HA3b compared with stimulation with NTX. The percentage of CD3 cells remained unchanged. These results suggest strongly that HA1 and HA3b demonstrate adjuvant activity via increasing IL6 production.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272395     DOI: 10.1099/mic.0.28421-0

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  31 in total

1.  Expression and purification of neurotoxin-associated protein HA-33/A from Clostridium botulinum and evaluation of its antigenicity.

Authors:  Ali Sayadmanesh; Firouz Ebrahimi; Abbas Hajizade; Mosayeb Rostamian; Hani Keshavarz
Journal:  Iran Biomed J       Date:  2013

2.  Mass Spectrometric Identification and Differentiation of Botulinum Neurotoxins through Toxin Proteomics.

Authors:  Suzanne R Kalb; John R Barr
Journal:  Rev Anal Chem       Date:  2013-08       Impact factor: 3.067

Review 3.  [Current outlook on botulinum toxin medications].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

4.  A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.

Authors:  Matthias Imhof; Ulrich Kühne
Journal:  J Clin Aesthet Dermatol       Date:  2011-10

5.  Genetic characterization of Clostridium botulinum associated with type B infant botulism in Japan.

Authors:  Kaoru Umeda; Yoshiyuki Seto; Tomoko Kohda; Masafumi Mukamoto; Shunji Kozaki
Journal:  J Clin Microbiol       Date:  2009-07-01       Impact factor: 5.948

Review 6.  Botulinum toxin drugs: future developments.

Authors:  D Dressler
Journal:  J Neural Transm (Vienna)       Date:  2008-03-28       Impact factor: 3.575

Review 7.  Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.

Authors:  Oussama El Yazami Adli; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

8.  Clinical Pharmacology of Botulinum Toxin Drugs.

Authors:  Dirk Dressler
Journal:  Handb Exp Pharmacol       Date:  2021

9.  [Essential blepharospasm : Practice-oriented therapy with botulinum toxin employing reduced treatment intervals].

Authors:  B Wabbels; P Roggenkämper
Journal:  Ophthalmologe       Date:  2012-01       Impact factor: 1.059

10.  Flu-like symptoms and associated immunological response following therapy with botulinum toxins.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic; Jordan Feld
Journal:  Neurotox Res       Date:  2013-05-16       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.